9 results about "IMMUNE STIMULANTS" patented technology

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The invention relates to the technical field of biomedical engineering, in particular to Pickering emulsion as well as a preparation method and application thereof. According to the invention, lentinan is selected as an immune agonist and is combined with PLGA, so that the immunocompetence of PLGA as an adjuvant is enhanced; the PLGA-coated lentinan can prevent the antigen from being directly exposed in an organic solvent to influence the activity of the antigen; compared with PLGA nanoparticles, the Pickering emulsion has a larger specific surface area and can adsorb more antigens; the Pickering emulsion has good fluidity and can increase the interaction between the PLGA nanoparticles and cell membranes, when the PLGA nanoparticles are in contact with antigen presenting cells (APCs), a large number of antigens are absorbed by the APCs, and the activated APCs can carry a large number of nanoparticles to enter lymph nodes, so that the Pickering emulsion has good lymph node targeting property. Upon uptake of a large number of antigens, the immune cells induce strong cellular or humoral immune responses in various ways.

The application provides a manganese dioxide nanomaterial, which comprises manganese dioxide nanoparticles and a carrier substance combined on the surface of the manganese dioxide nanoparticles; the carrier substance comprises CpG oligonucleotide and / or antigen; the antigen comprises protein antigen and / or polypeptide antigen. The manganese dioxide nanomaterial provided by the application greatly improves the immune stimulation of the immune adjuvant CpG, is used for improving the immune protection function of a vaccine, and solves the inherent defects that the oligonucleotide CpG as an immune stimulant is difficult to enter the lymph nodes of the body, and a large amount of CpG is needed to effectively improve the immune response; and as a vaccine adjuvant, the manganese dioxide nanomaterial can carry antigen, especially protein antigen, effectively improves the uptake of immune cells in the lymph nodes to the antigen, and thus improves the immunogenicity of the antigen. Meanwhile, the nanomaterial is biodegradable, and in a weak acid environment such as a lysosome, the nanomaterial can be gradually degraded into manganese ions (Mn 2+ ), and finally discharged out of the body.

The application relates to the technical field of medicines, and particularly discloses a novel immune stimulant, a preparation method and application thereof. The immune stimulant comprises an alpha-mannose modified imidazoquinoline derivative, an N-acetyl cysteine modified cytosine-guanine dinucleotide, a glycyrrhetinic acid-polyethylene glycol derivative, a phytic acid-glycine oligomer, a medicinal excipient and water for injection, three modified active ingredients are bridged by the phytic acid-glycine oligomer as a bridging unit, and a ternary coordination complex is formed through dynamic non-covalent coordination. The preparation method comprises the following steps: after raw materials are pretreated, the active ingredients are premixed, dissolved and solvent is recovered, then dynamic coordination reaction, ultrafiltration purification and concentration are carried out, and finally, a finished product is obtained through double-cavity preparation forming. The immune stimulant can be used for preparing a tumor immunotherapy, an anti-infection treatment, an immune deficiency disease auxiliary treatment drug or a vaccine adjuvant, and has the advantages of high active ingredient stability, good in-vivo delivery efficiency and outstanding synergistic effect.

The application discloses a kind of mannose modified graphene oxide-based nano drug delivery systems and its preparation method and application, belong to the technical field of biomedical materials and pharmaceutical preparations.The application solves the current free drug in vivo exposure shortage, lack of myeloid cell directional regulation, drug release uncontrollable and drug system biological compatibility problem.The application synthesizes mannose grafted ethylenediamine EDM, then with GO, EDM, EDC and NHS reaction, promote GO surface carboxyl and EDM amino form amide bond, obtain carrier, with DTX and Vadimezan loaded on carrier to obtain drug delivery system.The application uses GO as matrix, realizes receptor-mediated targeting nano-carrier system by surface functionalization of mannose, and it is used to deliver hydrophobic chemotherapeutic drugs and immune stimulants, which can be used for tumor treatment, including inhibiting primary tumor growth and metastasis-related lesions, and the effect is more obvious in combination with near-infrared light thermal response.

The application discloses a polylysine-based polymer adjuvant material and a preparation method and application thereof, and belongs to the technical field of biological medicines. The polylysine-based polymer adjuvant material has any one of structures shown in formula (I)-(III), has the dual functions of a carrier and an immune stimulant, has inherent immune stimulation activity, and has a clear structure, is easy to modify, has high biocompatibility, is degradable, and has good biological safety. The branched side chains of poly-L-lysine are modified first to obtain PLL-2V and PLL-4V, then are bonded with a five-membered, six-membered or seven-membered nitrogen-containing heterocyclic group or a heterocyclic small molecule with a benzene structure which is substituted by a carboxyl group or a hydroxyl group, to obtain the polylysine-based polymer adjuvant material. The polylysine-based polymer adjuvant material can be applied to the preparation of a vaccine preparation, and is of great significance to improving the preparation efficiency of the vaccine.